The offering prices are $22.0300 per share and $22.0290 per pre-funded warrant, producing a total offering price of $400,001,285.34. Tyra Biosciences (NASDAQ: TYRA) is the issuer and delivery was expected on or about September 15, 2026.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Chief Accounting Officer Theodore Alan Huizenga sold 1,283 shares at $13.57 per share. The transaction was completed on 15 September 2026.
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) awarded 171,774 derivative securities across two transactions. Dornan David, the company’s chief scientific officer, received the awards.
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) awarded Bryan Ball 183,266 derivative securities across two transactions. The transactions listed a per-share award price of $0.
Wilson Martin sold 75,364 Rocket Pharmaceuticals shares at $3.40 per share on 11 September 2026, in a transaction representing about 11.2% of his prior holding.
Jones Keith Anthony bought 10,000 shares of Humacyte, Inc. (NASDAQ: HUMA) at $0.56 per share. The purchase was reported on 14 September 2026.
Imunon, Inc. (NASDAQ: IMNN) awarded 4,211 shares to Chief Medical Officer Faller Douglas Vincent. The shares were issued at $1.47 per share. The filing identifies this as an award to the company’s medical officer.
Formela Jean Francois sold Korro Bio (NASDAQ: KRRO) shares at prices ranging from $13.99 to $14.12 per share. The transactions took place between Sep. 11 and Sep. 14, 2026, and carried SEC transaction code S.
The $19 monthly LifeMD (NASDAQ: LFMD) membership fee is fully waived, representing an annual value of $228. Customers must enroll, then pay only for visits, prescriptions or other services they use. A joint steering committee will oversee marketing, budgets, creative work, pricing, performance and …
Mobia Medical, Inc. (NASDAQ: MOBI) saw Leavitt Chase C. buy 2,000 shares at $10.30 per share. The buyer is identified with the designation “SEE REMARKS.